Krka has announced the launch of Robexera®, a fast-acting solution for the treatment of pain and inflammation associated with chronic osteoarthritis (OA) and soft tissue surgery in dogs.

Robexera (robenacoxib) is a highly selective, fast-acting COX2 NSAID formulation that delivers targeted anti-inflammatory pain relief with reduced systemic impact. Robenacoxib’s ability to persist at the site of inflammation enables Robexera to provide effective 24-hour pain relief on a simple, once-a-day dosing regime.

The product is presented as a flavoured chewable tablet for easier administration by pet owners. For simplicity when dispensing, it comes in four strengths with colour coded boxes, perforated blisters and a set of PIL sheets that convert to prescribing envelopes in each pack.

Commenting, Charlotte Read, Krka’s UK Key Account Manager, says: “Delivering reliable, cost-effective perioperative pain relief for soft tissue surgery is an everyday concern for veterinary practices, while OA is the most common cause of chronic pain in dogs5. This is why we’re particularly pleased to announce the first generic robenacoxib, Robexera.

“Bioequivalent to the originator product, Robexera provides fast-acting and targeted pain relief, giving enhanced value to veterinary practices and enabling them to offer their clients improved affordability, particularly for those whose animals are on long term pain-management programmes or have other health issues.”

Viktor Kozjan, General Manager Krka UK, added: “The launch of Robexera is further confirmation of Krka’s commitment to develop solutions that are tried and trusted but also flexible and affordable for our customers and their clients.”

Robexera is now available to order from all national UK veterinary wholesalers.

The Krka Team will be attending London Vet Show to discuss Robexera and the wider range of animal health solutions now offered for UK veterinary practice customers (stand S45).

Krka is one of the leading generic pharmaceutical companies in the world, and our medicines are used to treat more than 50 million human and animal patients worldwide every day. With over 50 years in developing animal health solutions Krka continues to bring innovation to the category with its branded generics.

Working closely with customers, Krka supplies licensed medicines that deliver effective and consistent performance in clinical practice. Krka’s Animal Health Portfolio provides high efficacy pharmaceuticals for both companion and food producing animals covering parasite control, infection management and pain relief. Key brands for companion animals include Milprazon CHEWABLE® and Prinocate®, for parasite management and Cladaxxa® for infection control.
​